INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES

(p-ISSN: 2348-5213: e-ISSN: 2348-5221)

www.ijcrcps.com

(A Peer Reviewed, Referred, Indexed and Open Access Journal)

DOI: 10.22192/ijcrcps **Coden: IJCROO(USA)** **Volume 12, Issue 10- 2025**

Review Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.10.005

Precision Diagnostics in Sickle Cell Anemia: Developing Algorithmic Models for Faster and More Accurate Detection

***Emmanuel Ifeanyi Obeagu**

Department of Biomedical and Laboratory Science, Africa University, Zimbabwe.
*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Biomedical and LaboratoryScience, Africa University, Zimbabwe, emmanuelobeagu@yahoo.com,
ORCID: 0000-0002-4538-0161

Abstract

Sickle cell anemia (SCA) is a hereditary hemoglobinopathy characterized by chronic hemolytic anemia, vaso-occlusive crises, and multi-organ complications. Timely and accurate diagnosis is essential for initiating effective preventive and therapeutic interventions. Traditional diagnostic methods, including hematologic assays and genetic testing, are effective but often labor-intensive, time-consuming, and limited in predictive capability. Recent advances in precision diagnostics, leveraging machine-assisted algorithmic models, offer the potential to accelerate detection, enhance accuracy, and support individualized care. By integrating hematologic, genetic, imaging, and clinical data, these algorithms can automate newborn screening, predict disease severity, and identify patients at risk for complications. This narrative review examines the development, applications, and challenges of algorithmic models in SCA diagnostics, highlighting their potential to transform clinical practice and improve outcomes.

Keywords: Sickle cell anemia, precision diagnostics, machine learning, algorithmic models, early detection

Introduction

Sickle cell anemia (SCA) is a genetic hemoglobinopathy resulting from a point mutation in the β-globin gene, which produces abnormal hemoglobin S. This molecular defect leads to red blood cell sickling, chronic hemolytic anemia, recurrent vaso-occlusive crises, and progressive multi-organ damage. SCA affects millions globally, with the highest prevalence in sub-Saharan Africa, India, the Middle East, and among populations of African descent worldwide. Early and accurate diagnosis is critical for initiating interventions such as prophylactic antibiotics, immunizations, hydroxyurea therapy, and regular monitoring to prevent complications and improve survival [1-3].Conventional diagnostic approaches, including complete blood counts, hemoglobin electrophoresis, and molecular genetic testing, remain the cornerstone of SCA detection. While effective, these methods are often resource-intensive, time-consuming, and limited in their ability to predict disease severity or long-term complications. These limitations are particularly challenging in resource-limited settings, where access to specialized laboratory infrastructure and comprehensive clinical care may be restricted [4-6].

Advances in precision diagnostics, particularly machine-assisted algorithmic models, have the potential to revolutionize SCA detection and management. By integrating multi-dimensional data—including hematologic profiles, genetic variants, imaging findings, and clinical histories—these algorithms can identify complex patterns not readily discernible through conventional methods. Such models facilitate faster, more accurate detection, risk stratification, and individualized patient care, from newborn screening to adult monitoring [7-8].This narrative review explores the evolving landscape of algorithmic models in SCA diagnostics. It examines applications across hematologic, genetic, and imaging domains, highlights multi-modal integration for comprehensive risk assessment, and discusses challenges in implementation. By synthesizing current evidence, this review aims to provide a framework for understanding how precision, algorithm-driven diagnostics can improve early detection, personalized care, and long-term outcomes in SCA.

Hematologic Markers: The Foundation for Algorithmic Models

Hematologic evaluation remains the cornerstone of SCA detection and provides essential data for developing algorithmic diagnostic models. Key laboratory parameters, including complete blood count (CBC), reticulocyte count, hemoglobin electrophoresis, and high-performance liquid chromatography (HPLC), reveal red blood cell morphology, hemoglobin composition, and the presence of hemolytic anemia. In neonates, these tests are critical for distinguishing between sickle cell trait and disease, enabling timely initiation of prophylactic care and early interventions [9-10].Machine-assisted algorithms enhance traditional hematologic screening by integrating multiple parameters simultaneously, improving diagnostic accuracy and reducing reliance on subjective interpretation. Supervised machine learning (ML) models, trained on large datasets of hematologic profiles, can differentiate SCA from other hemoglobinopathies and anemia types. Furthermore, predictive models can analyze longitudinal hematologic trends to identify patients at higher risk of complications, such as vaso-occlusive crises, stroke, or organ dysfunction, supporting proactive management strategies [11-13].

Beyond diagnosis, algorithmic evaluation of hematologic data facilitates risk stratification and monitoring over time. Automated systems can flag abnormal patterns in blood counts or hemoglobin fractions, prompting clinicians to intervene before severe clinical manifestations occur. In resource-limited settings, such algorithms can expand coverage by enabling high-throughput, standardized screening without requiring extensive specialist input [14-16].Integrating hematologic markers into machine-assisted workflows lays the groundwork for multi-modal diagnostic pathways, bridging laboratory findings with genetic, imaging, and clinical data. This approach ensures early, accurate, and comprehensive detection, forming a critical foundation for precision diagnostics and individualized care in SCA [17-18].

Genetic Diagnostics: Definitive Confirmation and Subtype Identification

Genetic testing serves as the definitive method for confirming SCA and distinguishing among its various subtypes. The disease arises from a point mutation in the β-globin gene (HBB), resulting in the substitution of valine for glutamic acid at the sixth position of the β-globin chain. This molecular alteration produces hemoglobin S, which underlies red blood cell sickling, hemolysis, and vaso-occlusion [19-20].Traditional molecular diagnostics, including polymerase chain reaction (PCR), DNA sequencing, and next-generation sequencing, enable precise identification of HbS and related variants such as HbC or compound heterozygotes. Genetic testing not only confirms disease presence but also allows genotype-based risk stratification, guiding treatment decisions and prognostic evaluation. For example, patients with HbSS genotype typically experience more severe clinical manifestations than those with HbSC or HbS/β-thalassemia variants [21-22].

Machine-assisted diagnostic models further enhance genetic evaluation by integrating genotype data with hematologic and clinical information. Predictive algorithms can correlate specific genetic variants with disease severity, likelihood of complications, and response to therapies such as hydroxyurea or transfusion regimens. Deep learning models trained on large genomic datasets can also detect rare mutations or compound heterozygous patterns that might otherwise be missed, improving diagnostic precision and enabling personalized care planning [23].Incorporating genetic diagnostics into multi-modal algorithmic frameworks provides definitive confirmation while informing individualized risk assessment and management strategies. By leveraging genotype data alongside hematologic, imaging, and clinical markers, machine-assisted approaches create a comprehensive patient profile, supporting proactive interventions and tailored therapy in patients with SCA [24].

Imaging Biomarkers: Detecting Early Organ Stress

SCA is associated with progressive organ damage that often develops silently before clinical symptoms emerge. Organs commonly affected include the spleen, kidneys, liver, heart, lungs, and central nervous system. Early detection of subclinical organ injury is critical for preventing irreversible damage and optimizing patient outcomes. Imaging modalities provide a non-invasive means to assess structural and functional changes, offering valuable input for algorithmic diagnostic models [25].Common imaging techniques in SCA include Doppler ultrasonography, echocardiography, and magnetic resonance imaging (MRI). For example, transcranial Doppler (TCD) ultrasonography measures cerebral blood flow velocities and is a validated predictor of stroke risk in children. Renal imaging can detect early nephropathy, while echocardiography identifies cardiac remodeling or pulmonary hypertension resulting from chronic hemolysis. MRI provides high-resolution assessment of organ morphology and tissue integrity, aiding detection of subtle liver, spleen, or brain changes [26-27].Machine-assisted algorithms enhance the utility of imaging by automating pattern recognition and quantitative analysis. Deep learning models can identify subtle abnormalities in organ structure or perfusion that may be overlooked by human interpretation. Integrating imaging data with hematologic and genetic markers allows predictive models to assess individual risk profiles, identify patients likely to develop complications, and guide timely interventions [28].

Developing Multi-Modal Algorithmic Models

The complexity and heterogeneity of SCA necessitate diagnostic approaches that integrate data from multiple domains. Multi-modal algorithmic models combine hematologic, genetic, imaging, and clinical information to provide comprehensive, precise, and individualized assessments. By synthesizing diverse datasets, these models enhance diagnostic accuracy, accelerate detection, and enable personalized risk stratification [29].A typical multi-modal pathway begins with hematologic screening, which identifies patients with abnormal red blood cell indices or hemoglobin patterns. Positive findings are confirmed and refined through genetic diagnostics, which provide definitive diagnosis and subtype classification. Imaging biomarkers then contribute critical information regarding early organ stress, allowing detection of subclinical complications before symptoms appear. Longitudinal clinical data, including patient history, laboratory trends, and prior complications, further inform predictive modeling [30-31].Machine learning and deep learning algorithms play a central role in integrating these data streams. Predictive models can generate individualized risk scores, flag high-risk patients, and guide targeted interventions. For instance, combining transcranial Doppler velocities, genotype, and hematologic trends can help identify children at elevated risk of stroke, prompting early prophylactic therapy. In adults, multi-modal algorithms can anticipate organ dysfunction, inform therapy adjustments, and prioritize follow-up for high-risk individuals [32].

Challenges and Considerations in Implementation

While machine-assisted, multi-modal algorithmic models hold significant promise for SCA diagnostics, several challenges must be addressed to ensure effective, equitable, and sustainable deployment.

Data Quality and Standardization: Accurate predictions depend on high-quality, standardized datasets. Variability in laboratory methods, incomplete clinical records, and population-specific genetic differences can compromise algorithm performance. Ensuring consistent data collection and rigorous validation is essential [33-34].

Resource Limitations: Many regions with a high prevalence of SCA, particularly sub-Saharan Africa and low-resource areas, lack infrastructure for high-throughput genetic testing, advanced imaging, or computational platforms. These limitations may restrict access to algorithmic diagnostics and hinder implementation at scale [35].

Clinical Integration: Algorithms are intended to complement, not replace, clinician expertise. Successful adoption requires integration into clinical workflows, user-friendly interfaces, and adequate training for healthcare providers. Overreliance on “black-box” models or insufficient understanding of outputs can limit their effectiveness [36].

Ethical and Regulatory Considerations: Patient privacy, data security, and equitable access are critical. Algorithms must be transparent, interpretable, and validated across diverse populations to avoid perpetuating disparities in care. Regulatory frameworks for AI-driven diagnostics are evolving and must align with clinical standards [37].

Sustainability and Maintenance: Algorithmic models require continuous updates, retraining with new data, and long-term maintenance to remain accurate and relevant. Without sustainable infrastructure and funding, models risk becoming obsolete or underutilized [38].

Conclusion

Machine-assisted, multi-modal algorithmic models represent a transformative advance in the diagnosis and management of sickle cell anemia (SCA). By integrating hematologic, genetic, imaging, and clinical data, these models enable faster, more accurate detection, individualized risk stratification, and proactive patient management across the lifespan—from newborn screening to adult care.While challenges related to data quality, resource limitations, clinical integration, and ethical considerations remain, advances in machine learning and computational medicine offer promising solutions. Algorithm-driven diagnostics have the potential to improve early identification of at-risk patients, optimize therapy, prevent complications, and enhance long-term outcomes. Future efforts should focus on validating these models in diverse populations, ensuring equitable access, and embedding algorithmic tools seamlessly into clinical workflows. By bridging traditional diagnostics with advanced computational approaches, multi-modal algorithmic models can pave the way toward precision medicine and more effective, personalized care for individuals living with SCA.

References

1. Ansari, J., Moufarrej, Y. E., Pawlinski, R., &Gavins, F. N. E. (2018). Sickle cell disease: a malady beyond a hemoglobin defect in cerebrovascular disease. *Expert review of hematology*, *11*(1), 45–55. https://doi.org/10.1080/17474086.2018.1407240
2. Obeagu, E. I., &Olateju, O. R. (2025). Integrating sickle cell disease care into primary healthcare in Uganda: a narrative review. *Annals of medicine and surgery (2012)*, *87*(9), 5918–5924. https://doi.org/10.1097/MS9.0000000000003713
3. McGann, P. T., & Hoppe, C. (2017). The pressing need for point-of-care diagnostics for sickle cell disease: A review of current and future technologies. *Blood cells, molecules & diseases*, *67*, 104–113. https://doi.org/10.1016/j.bcmd.2017.08.010
4. Obeagu E. I. (2025). Strategies for reducing child mortality due to sickle cell disease in Uganda: a narrative review. *Annals of medicine and surgery (2012)*, *87*(6), 3279–3288. https://doi.org/10.1097/MS9.0000000000002981
5. Hippisley-Cox, J., & Coupland, C. A. (2025). Development and external validation of prediction algorithms to improve early diagnosis of cancer. *Nature communications*, *16*(1), 3660. https://doi.org/10.1038/s41467-025-57990-5
6. Obeagu E. I. (2025). Thrombosis risk in sickle cell disease with HIV co-infection: unraveling the complex interactions and clinical implications - a narrative review. *Annals of medicine and surgery (2012)*, *87*(8), 5070–5076. https://doi.org/10.1097/MS9.0000000000003533
7. Chong, P. L., Vaigeshwari, V., Mohammed Reyasudin, B. K., Noor Hidayah, B. R. A., Tatchanaamoorti, P., Yeow, J. A., & Kong, F. Y. (2025). Integrating artificial intelligence in healthcare: applications, challenges, and future directions. *Future science OA*, *11*(1), 2527505. https://doi.org/10.1080/20565623.2025.2527505
8. Obeagu E. I. (2025). Clotting, inflammation, and immunity: the multifaceted role of platelets in HIV and sickle cell disease - a narrative review. *Annals of medicine and surgery (2012)*, *87*(9), 5878–5886. https://doi.org/10.1097/MS9.0000000000003677
9. Arishi, W. A., Alhadrami, H. A., &Zourob, M. (2021). Techniques for the Detection of Sickle Cell Disease: A Review. *Micromachines*, *12*(5), 519. https://doi.org/10.3390/mi12050519
10. Obeagu E. I. (2025). Adhesion molecules in focus: mechanistic pathways and therapeutic avenues in sickle cell vaso-occlusion - a narrative review. *Annals of medicine and surgery (2012)*, *87*(9), 5775–5783. https://doi.org/10.1097/MS9.0000000000003619

11. Carden, M. A., Fasano, R. M., & Meier, E. R. (2020). Not all red cells sickle the same: Contributions of the reticulocyte to disease pathology in sickle cell anemia. *Blood reviews*, *40*, 100637. https://doi.org/10.1016/j.blre.2019.100637
12. Meier, E. R., Wright, E. C., & Miller, J. L. (2014). Reticulocytosis and anemia are associated with an increased risk of death and stroke in the newborn cohort of the Cooperative Study of Sickle Cell Disease. *American journal of hematology*, *89*(9), 904–906. https://doi.org/10.1002/ajh.23777
13. Higgins J. M. (2015). Red blood cell population dynamics. *Clinics in laboratory medicine*, *35*(1), 43–57. https://doi.org/10.1016/j.cll.2014.10.002
14. Obeagu E. I. (2025). Public-private partnerships in tackling sickle cell disease in Uganda: a narrative review. *Annals of medicine and surgery (2012)*, *87*(6), 3339–3355. https://doi.org/10.1097/MS9.0000000000003082
15. Liu, J., Gou, Y., Yang, W., Wang, H., Zhang, J., Wu, S., Liu, S., Tao, T., Tang, Y., Yang, C., Chen, S., Wang, P., Feng, Y., Zhang, C., Liu, S., Peng, X., & Zhang, X. (2025). Development and application of machine learning models for hematological disease diagnosis using routine laboratory parameters: a user-friendly diagnostic platform. *Frontiers in medicine*, *12*, 1605868. https://doi.org/10.3389/fmed.2025.1605868
16. Obeagu E. I. (2025). Hypoxia, Inflammation, and Cytokine Crosstalk in Sickle Cell Disease: From Mechanisms to Modulation- A Narrative Review. *Pediatric health, medicine and therapeutics*, *16*, 217–225. https://doi.org/10.2147/PHMT.S544217
17. Asad, S., Ahmed, I., & Ali, N. (2017). Utility of Peripheral Film Findings and its Correlation with Automated Analyzer - An Audit from Tertiary Care Hospital. *Journal of laboratory physicians*, *9*(1), 1–4. https://doi.org/10.4103/0974-2727.189233
18. Mbayabo, G., LumbalaKabuyi, P., Ngole, M., Lumaka, A., Race, V., Maisin, D., Gruson, D., Matthijs, G., Minga, T. M., Devriendt, K., Van Geet, C., &Tshilobo, P. L. (2022). Value of DNA testing in the diagnosis of sickle-cell anemia in childhood in an environment with a high prevalence of other causes of anemia. *Journal of clinical laboratory analysis*, *36*(8), e24593. https://doi.org/10.1002/jcla.24593
19. Arishi, W. A., Alhadrami, H. A., &Zourob, M. (2021). Techniques for the Detection of Sickle Cell Disease: A Review. *Micromachines*, *12*(5), 519. https://doi.org/10.3390/mi12050519
20. Yang, N., Zhang, H., Han, X., Liu, Z., & Lu, Y. (2024). Advancements and applications of loop-mediated isothermal amplification technology: a comprehensive overview. *Frontiers in microbiology*, *15*, 1406632. https://doi.org/10.3389/fmicb.2024.1406632
21. Figueiredo M. S. (2015). The compound state: Hb S/beta-thalassemia. *Revistabrasileira de hematologia e hemoterapia*, *37*(3), 150–152. https://doi.org/10.1016/j.bjhh.2015.02.008
22. Ozgüç M. (2011). Genetic testing: predictive value of genotyping for diagnosis and management of disease. *The EPMA journal*, *2*(2), 173–179. https://doi.org/10.1007/s13167-011-0077-y
23. Kalpatthi, R., &Novelli, E. M. (2018). Measuring success: utility of biomarkers in sickle cell disease clinical trials and care. *Hematology. American Society of Hematology. Education Program*, *2018*(1), 482–492. https://doi.org/10.1182/asheducation-2018.1.482
24. Jordan, L. C., Roberts Williams, D. O., Rodeghier, M. J., Covert Greene, B. V., Ponisio, M. R., Casella, J. F., McKinstry, R. C., Noetzel, M. J., Kirkham, F. J., Meier, E. R., Fuh, B., McNaull, M., Sarnaik, S., Majumdar, S., McCavit, T. L., & DeBaun, M. R. (2018). Children with sickle cell anemia with normal transcranial Doppler ultrasounds and without silent infarcts have a low incidence of new strokes. *American journal of hematology*, *93*(6), 760–768. https://doi.org/10.1002/ajh.25085

25. Vancauwenberghe, T., Snoeckx, A., Vanbeckevoort, D., Dymarkowski, S., &Vanhoenacker, F. M. (2015). Imaging of the spleen: what the clinician needs to know. *Singapore medical journal*, *56*(3), 133–144. https://doi.org/10.11622/smedj.2015040
26. Qhalib, H. A., & Zain, G. H. (2014). Hepatobiliary Complications of Sickle Cell Disease among Children Admitted to Al Wahda Teaching Hospital, Aden, Yemen. *Sultan Qaboos University medical journal*, *14*(4), e556–e560.
27. Czap, A. L., &Sheth, S. A. (2021). Overview of Imaging Modalities in Stroke. *Neurology*, *97*(20 Suppl 2), S42–S51. https://doi.org/10.1212/WNL.0000000000012794
28. Gao, X., Lv, Q., & Hou, S. (2023). Progress in the Application of Portable Ultrasound Combined with Artificial Intelligence in Pre-Hospital Emergency and Disaster Sites. *Diagnostics (Basel, Switzerland)*, *13*(21), 3388. https://doi.org/10.3390/diagnostics13213388
29. Arishi, W. A., Alhadrami, H. A., &Zourob, M. (2021). Techniques for the Detection of Sickle Cell Disease: A Review. *Micromachines*, *12*(5), 519. https://doi.org/10.3390/mi12050519
30. Olupot-Olupot, P., Connon, R., Kiguli, S., Opoka, R. O., Alaroker, F., Uyoga, S., Nakuya, M., Okiror, W., Nteziyaremye, J., Ssenyondo, T., Nabawanuka, E., Kayaga, J., Williams Mukisa, C., Amorut, D., Muhindo, R., Frost, G., Walsh, K., Macharia, A. W., Gibb, D. M., Walker, A. S., … Williams, T. N. (2022). A predictive algorithm for identifying children with sickle cell anemia among children admitted to hospital with severe anemia in Africa. *American journal of hematology*, *97*(5), 527–536. https://doi.org/10.1002/ajh.26492
31. Uçucu, S., Karabıyık, T., &Azik, F. (2022). Difficulties in the diagnosis of HbS/beta thalassemia: Really a mild disease?.*Journal of medical biochemistry*, *41*(1), 32–39. https://doi.org/10.5937/jomb0-30420
32. Cetinic, I., de Lange, C., Lagerstrand, K., Kindblom, J. M., Sjögren, L., &Hebelka, H. (2025). Applicability of multiple quantitative ultrasound liver biomarkers in children and adolescents with severe obesity. *BMC pediatrics*, *25*(1), 390. https://doi.org/10.1186/s12887-025-05750-1
33. Obeagu E. I. (2025). Sickle cell anemia and social justice: a pathway to equitable healthcare in Uganda. *Annals of medicine and surgery (2012)*, *87*(11), 7283–7293. https://doi.org/10.1097/MS9.0000000000003910
34. Ally, M., &Balandya, E. (2023). Current challenges and new approaches to implementing optimal management of sickle cell disease in sub-Saharan Africa. *Seminars in hematology*, *60*(4), 192–199. https://doi.org/10.1053/j.seminhematol.2023.08.002
35. Heidt, B., Siqueira, W. F., Eersels, K., Diliën, H., van Grinsven, B., Fujiwara, R. T., &Cleij, T. J. (2020). Point of Care Diagnostics in Resource-Limited Settings: A Review of the Present and Future of PoC in Its Most Needed Environment. *Biosensors*, *10*(10), 133. https://doi.org/10.3390/bios10100133
36. Ghoneim, A. M. E., Mohamed, S. K., Hetta, W. A., &Alkaphoury, M. G. (2025). Role of transcranial Doppler ultrasound in early assessment of acute post-traumatic brain injury. *Medicine*, *104*(42), e45171. https://doi.org/10.1097/MD.0000000000045171
37. Zhang, B., Wan, Z., Luo, Y., Zhao, X., Samayoa, J., Zhao, W., & Wu, S. (2025). Multimodal integration strategies for clinical application in oncology. *Frontiers in pharmacology*, *16*, 1609079. https://doi.org/10.3389/fphar.2025.1609079

38. Boardman, F. K., Clark, C., Jungkurth, E., & Young, P. J. (2020). Social and cultural influences on genetic screening programme acceptability: A mixed-methods study of the views of adults, carriers, and family members living with thalassemia in the UK. *Journal of genetic counseling*, *29*(6), 1026–1040. https://doi.org/10.1002/jgc4.1231

Access this Article in Online	
	Website: www.ijcrcps.com
Quick Response Code	Subject: Haematology
DOI: 10.22192/ijcrcps.2025.12.10.005	

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2025). Precision Diagnostics in Sickle Cell Anemia: Developing Algorithmic Models for Faster and More Accurate Detection. Int. J. Curr. Res. Chem. Pharm. Sci. 12(10): 42-49.
DOI: http://dx.doi.org/10.22192/ijcrcps.2025.12.10.005

